BOSTON , Oct. 26, 2022 (GLOBE NEWSWIRE) — Block & Leviton is investigating Y-mAbs Therapeutics, Inc. (NASDAQ: YMAB) for potential securities law violations. Investors who have lost money in their Y-mAbs Therapeutics, Inc. investment should contact the firm to learn more about how they might recover those losses. For more details, visit https://www.blockleviton.com/cases/ymab.
What is this all about?
On October 26, 2022, briefing documents posted to the U.S. Food and Drug Administration (FDA) website identified concerns by FDA scientists regarding data submitted by Y-mAbs Therapeutics, Inc. in support of the company’s Biologics License Application (BLA) for its neuroblastoma therapy, omburtamab.
Key issues identified by the FDA include differences between study and control populations and their impact on the control population as a comparator, results from FDA conducted analyses to examine bias, and a lack of reliable response rate data for supportive evidence of the treatment effect of omburtamab.
Previously, on April 1, 2022, Y-mAbs Therapeutics resubmitted its BLA for omburtamab after the FDA issued a Refuse to File letter regarding the company’s marketing application for the drug in children with CNS/leptomeningeal metastasis from neuroblastoma, citing portions of two modules in the application requiring further detail.
Shares of Y-mAbs Therapeutics, Inc. stock dropped more than 20% in intraday trading on October 26, 2022.
Who is eligible?
Anyone who purchased Y-mAbs Therapeutics, Inc. stock and has lost money may be eligible, whether or not they have sold their investment. Investors should contact Block & Leviton to learn more.
What is Block & Leviton doing?
Block & Leviton is investigating whether the Company committed securities law violations and may file an action to attempt to recover losses on behalf of investors who have lost money.
What should you do next?
If you’ve lost money on your investment, you should contact Block & Leviton to learn more via our case website, by email at [email protected], or by phone at (617) 398-5600.
Why should you contact Block & Leviton?
Many law firms have issued releases about this matter; most of those firms do not actually litigate securities class actions. Block & Leviton is a law firm that actually litigates cases. We are dedicated to obtaining significant recoveries on behalf of defrauded investors through active litigation in the federal courts across the country. Many of the nation’s top institutional investors hire us to represent their interests. You can learn more about us at our website, www.blockleviton.com, or call (617) 398-5600 or email [email protected] with any questions.
This notice may constitute attorney advertising.
CONTACT:
BLOCK & LEVITON LLP
260 Franklin St., Suite 1860
Boston, MA 02110
Phone: (617) 398-5600
Email: [email protected]
SOURCE: Block & Leviton LLP
www.blockleviton.com
- Metagenomi Presents Compact SMART Editing Platform at AIChE 7th International Conference on CRISPR Technologies - October 14, 2024
- Shareholders that lost money on Sage Therapeutics, Inc. (SAGE) Urged to Join Class Action – Contact Levi & Korsinsky to Learn More - October 14, 2024
- Class Action Filed Against Sprinklr, Inc. (CXM) – October 15, 2024 Deadline to Join – Contact Levi & Korsinsky - October 14, 2024